Cabozantinib S-Malate in Treating Patients With Neuroendocrine Tumors

Basic Study Information

Purpose:
This randomized phase III trial studies cabozantinib S-malate to see how well it works compared with placebo in treating patients with neuroendocrine tumors that have spread to nearby tissues or lymph nodes, have spread to other places in the body, or cannot be removed by surgery after previous treatment with everolimus. Cabozantinib S-malate is a chemotherapy drug known as a tyrosine kinase inhibitor, and it targets specific tyrosine kinase receptors, that when blocked, may slow tumor growth.

Lead Researcher (Principal Investigator)

Lead Researcher: Aram Hezel

Study Contact Information

Additional Study Details

Return to Search